People: Thrive Law; Addleshaw Goddard; Ellis Patents; and more

Thrive Law and Karen Eckstein Ltd have confirmed the appointment of Karen Eckstein as head of risk to Thrive.

She will be joined by Polly Coram as deputy head. Eckstein and Coram will be looking after Leeds-based Thrive’s internal risk management as well as their own clients’ professional risk issues.

The collaboration between Thrive Law and Karen Eckstein Ltd arises from a long-standing relationship between the two businesses and their founders and enables Thrive to offer additional services to their clients.

Jodie Hill, managing partner at Thrive Law, said: “Having worked with Karen and known her for a long time, I have always admired her tenacity and collaborative approach as a leader.

“She brings a wealth of experience to the senior team, and I am excited to welcome her and Polly to our Thrive Tribe.”

Eckstein added: “I have known Jodie for many years, both as a friend and more recently as a client of Thrive in their HR package.

“We share the same ethos, and our values align. I am really looking forward to working more closely with Jodie and the Thrive Tribe on all things risk related.”

:::

The number of partners in Addleshaw Goddard’s Global Investigations practice is rising to 10.

It follows the arrival from Jones Day of Harriet Territt, who has over 20 years’ experience resolving significant financial regulatory, investigations, compliance and dispute issues for a client portfolio comprising several of the world’s largest banks and multinational companies.

She also has a growing practice working with clients on liability, risk, and governance issues in relation to emerging technologies and fintech, particularly blockchain and digital assets, decentralised finance, AI implementations, and consumer facing products.

Territt regularly advises on complex issues related to global financial sanctions and money laundering rules, including representing clients before the Financial Conduct Authority and the Office of Financial Sanctions Implementation.

She has undertaken highly confidential internal investigations and compliance assurance reviews in the financial and regulated sectors.

Leeds-based Harriet is the first partner hire in Leeds for the Global Investigations practice.

The practice specialises in advising on matters across all aspects of corporate crime, including money laundering, fraud, bribery and corruption, asset recovery and sanctions, health and safety and environmental.

It also takes more unusual instructions relating to blackmail, perverting the course of justice, criminal contempt of court and has a growing expertise in investigations and enforcement actions relating to cryptoassets.

Nichola Peters, head of the global investigations practice at Addleshaw Goddard, said: “Harriet has considerable experience across a number of our strategic growth areas and will add very significantly to our bench strength and experience in litigation and contentious regulatory work, risk and compliance assurance, and investigations, especially given the increasing focus on ESG and reforms to director liability and accountability, enforceable by ARGA.

“Harriet’s interest in digital assets and fintech introduces an exciting dimension to our practice, particularly disputes and investigations arising out of risk, governance and systems controls relating to such issues.”

:::

Rillington-based Ellis Patents has further strengthened its sales team by appointing Kirby Gregory as a sales and customer service executive.  

Gregory, who comes from Scarborough, joins an eight-strong sales team which is responsible for securing specifications for, and sales of, the company’s cable cleats around the world.  

Kelly Brown, sales director, said: “Our sales operation covers 50 different export markets, with local distributors in each, as well as our domestic sales operation.

“Kirby’s job is to ensure all the different elements of the sales process run smoothly so no opportunities are missed or customers left lacking in terms of service.

“It’s certainly a big job, but working alongside fellow sales and customer service executive, Claire Dale, it’s one I’m confident she’ll excel in.” 

Gregory said: “I’m very excited to be joining Ellis Patents. The company has a great reputation – both as a manufacturer of cable cleats and a local employer – and I’m looking forward to playing my part in its continued success.”

:::

Quality and compliance software expert, Radar Healthcare, has appointed former chief executive officer of the National Institute for Health and Care Excellence (NICE), Professor Gillian Leng, to its board of non-executive directors.

Leng was appointed NICE’s CEO in April 2020 following a 13- year tenure as deputy chief executive for the organisation.

At the helm during the pandemic, she oversaw development of the Covid-19 guidelines. She was instrumental in the creation of NICE’s five-year strategy and set out updated methods and processes to put NICE at the forefront of evaluating new medicines, devices and diagnostics.

Her career spans more than 30 years working across public health, healthcare and social care, within life science industries, patient organisations, local and national Government and academia.

Leng said: “I’m excited to be working with Radar Healthcare to support its growth with key healthcare strategies.

“Throughout my career, I’ve focused on searching for the clinical evidence to not only inspire change, but to also make that change long lasting so it can directly benefit patients.

“As the health sector undergoes its digital transformation, technology partners such as Radar Healthcare are playing an increasingly vital role in providing the evidence needed to enable informed decisions and positive change.”

Paul Johnson, CEO of Leeds-based Radar Healthcare, said: “Gillian Leng’s career, and the long list of accomplishments she’s earned along the way, are nothing short of remarkable.

“Her unique perspective and experience, along with a vision we both share about the role of technology and its ability to provide healthcare insights to deliver better patient outcomes, will play a key role in our continued success.”